C4 Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
C4 Therapeutics has a total shareholder equity of $246.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $376.5M and $130.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$253.68m |
| Equity | US$246.11m |
| Total liabilities | US$130.34m |
| Total assets | US$376.45m |
Recent financial health updates
No updates
Recent updates
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04C4 Therapeutics closes $181M capital raise
Jun 21C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial
Jun 14C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy
Jun 07Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
Jun 02C4 Therapeutics to advance CFT8919 into IND-enabling studies
May 26Read This Before Selling C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares
Mar 15Financial Position Analysis
Short Term Liabilities: CCCC's short term assets ($271.2M) exceed its short term liabilities ($42.8M).
Long Term Liabilities: CCCC's short term assets ($271.2M) exceed its long term liabilities ($87.6M).
Debt to Equity History and Analysis
Debt Level: CCCC is debt free.
Reducing Debt: CCCC had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CCCC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CCCC has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 34.7% each year.